GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valerio Therapeutics (XPAR:ALVIO) » Definitions » Gross Margin %

Valerio Therapeutics (XPAR:ALVIO) Gross Margin % : 82.56% (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Valerio Therapeutics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Valerio Therapeutics's Gross Profit for the six months ended in Dec. 2023 was €1.49 Mil. Valerio Therapeutics's Revenue for the six months ended in Dec. 2023 was €1.80 Mil. Therefore, Valerio Therapeutics's Gross Margin % for the quarter that ended in Dec. 2023 was 82.56%.

Warning Sign:

Valerio Therapeutics gross margin has been in long-term decline. The average rate of decline per year is -7%.


The historical rank and industry rank for Valerio Therapeutics's Gross Margin % or its related term are showing as below:

XPAR:ALVIO' s Gross Margin % Range Over the Past 10 Years
Min: 64.38   Med: 90.63   Max: 98.87
Current: 70.39


During the past 13 years, the highest Gross Margin % of Valerio Therapeutics was 98.87%. The lowest was 64.38%. And the median was 90.63%.

XPAR:ALVIO's Gross Margin % is ranked better than
62.48% of 741 companies
in the Biotechnology industry
Industry Median: 59.43 vs XPAR:ALVIO: 70.39

Valerio Therapeutics had a gross margin of 82.56% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Valerio Therapeutics was -7.00% per year.


Valerio Therapeutics Gross Margin % Historical Data

The historical data trend for Valerio Therapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valerio Therapeutics Gross Margin % Chart

Valerio Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 91.84 80.46 90.94 64.38 70.39

Valerio Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 94.99 - 81.15 - 82.56

Competitive Comparison of Valerio Therapeutics's Gross Margin %

For the Biotechnology subindustry, Valerio Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valerio Therapeutics's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valerio Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Valerio Therapeutics's Gross Margin % falls into.



Valerio Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Valerio Therapeutics's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=1.3 / 1.8
=(Revenue - Cost of Goods Sold) / Revenue
=(1.8 - 0.533) / 1.8
=70.39 %

Valerio Therapeutics's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=1.5 / 1.8
=(Revenue - Cost of Goods Sold) / Revenue
=(1.8 - 0.314) / 1.8
=82.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Valerio Therapeutics  (XPAR:ALVIO) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Valerio Therapeutics had a gross margin of 82.56% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Valerio Therapeutics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Valerio Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Valerio Therapeutics (XPAR:ALVIO) Business Description

Traded in Other Exchanges
Address
49 Boulevard du General, Martial Valin, Paris, FRA, 75015
Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.

Valerio Therapeutics (XPAR:ALVIO) Headlines

No Headlines